Skip to main content
. 2020 Feb 6;40(1):25-35. doi: 10.5144/0256-4947.2020.25

Table 2.

Management and outcomes (N=190)

Cut-through hysterectomy
 No 187 (98.4)
 Yes 3 (1.6)
Radical hysterectomy
 No 134 (70.5)
 Initial 47 (24.7)
 After RT/CT 9 (4.7)
Radiotherapy
 No 42 (22.1)
 Initial 119 (62.6)
 Adjuvant 29 (15.3)
Chemotherapy
 No 63 (33.2)
 Concurrent 101 (53.2)
 Adjuvant 25 (13.2)
Systemic chemotherapy
 No 178 (93.7)
 Yes 12 (6.3)
Palliative care
 No 180 (94.7)
 Yes 9 (4.7)
 Missing data 1 (0.5)
Follow-up and outcome
Total follow-up time (months) 37.0 (46-62)
Persistent tumor
 Yes 7 (3.7)
Recurrence
 Recurrence rate 49 (25.8)
 Time-to-recurrence (months) 13.0 (6.0-28.0)
Mortality
 Mortality rate 89 (46.8)
 Time-to-death (months) 20 (9.0-46.5)
5-year follow-up status
 Alive without disease 53 (27.9)
 Alive with disease 8 (4.2)
 Deceased 73 (38.4)
 Unknown (FU<5 years) 56 (29.5)

Data are number (%) or median (IQR) unless noted otherwise. Because of missing data, not all values sum to the total.